Cardio Diagnostics Holdings Inc to Attend 41st Annual JP Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Jan 4, 2023--
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023.
The JP Morgan Healthcare Conference, which will be held in San Francisco, is an annual event that brings together the leaders and innovators of the healthcare industry. The event is a gathering place for the healthcare industry’s leaders and executives to exchange information, showcase new technologies and connect with potential customers and investors. It includes presentations, panel discussions, and networking events with some of the most innovative companies and investors in healthcare. Executives from biotech, pharmaceutical, and medical device companies, venture capitalists, private equity firms, and healthcare service providers will attend. Cardio Diagnostics is attending to discuss its breakthrough solutions in cardiovascular disease with potential strategic partners, investors, and equity analysts.
About Cardio Diagnostics
Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests derived from a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine TM (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “should,” “believe,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™, Cardio’s initial test, is accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s common stock on Nasdaq; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its tests, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that could serve the same or similar functions as the Company’s products and services; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical tests conducted using the Company’s products and services; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230104005943/en/
Meesha Dogan, Ph.D.
email@example.comMedia & Public Relations:
KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS
INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES TECHNOLOGY GENETICS ARTIFICIAL INTELLIGENCE CARDIOLOGY BIOTECHNOLOGY
SOURCE: Cardio Diagnostics Holdings Inc
Copyright Business Wire 2023.
PUB: 01/04/2023 04:15 PM/DISC: 01/04/2023 04:16 PM